X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ABBOTT INDIA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ABBOTT INDIA GLENMARK PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 22.5 40.4 55.7% View Chart
P/BV x 3.5 9.6 36.8% View Chart
Dividend Yield % 0.3 0.7 47.6%  

Financials

 GLENMARK PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
ABBOTT INDIA
Mar-18
GLENMARK PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs9936,110 16.3%   
Low Rs7293,996 18.3%   
Sales per share (Unadj.) Rs325.51,552.2 21.0%  
Earnings per share (Unadj.) Rs39.3188.8 20.8%  
Cash flow per share (Unadj.) Rs48.7196.4 24.8%  
Dividends per share (Unadj.) Rs2.0055.00 3.6%  
Dividend yield (eoy) %0.21.1 21.3%  
Book value per share (Unadj.) Rs159.2796.6 20.0%  
Shares outstanding (eoy) m282.1721.25 1,327.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.3 81.3%   
Avg P/E ratio x21.926.8 81.9%  
P/CF ratio (eoy) x17.725.7 68.8%  
Price / Book Value ratio x5.46.3 85.3%  
Dividend payout %5.129.1 17.5%   
Avg Mkt Cap Rs m242,991107,376 226.3%   
No. of employees `00013.03.3 390.3%   
Total wages/salary Rs m16,4083,937 416.8%   
Avg. sales/employee Rs Th7,083.99,929.3 71.3%   
Avg. wages/employee Rs Th1,265.41,185.1 106.8%   
Avg. net profit/employee Rs Th855.11,207.7 70.8%   
INCOME DATA
Net Sales Rs m91,85732,985 278.5%  
Other income Rs m3741,170 31.9%   
Total revenues Rs m92,23034,155 270.0%   
Gross profit Rs m20,3675,245 388.3%  
Depreciation Rs m2,644162 1,632.9%   
Interest Rs m2,37338 6,212.6%   
Profit before tax Rs m15,7246,215 253.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8272,203 173.7%   
Profit after tax Rs m11,0884,012 276.4%  
Gross profit margin %22.215.9 139.4%  
Effective tax rate %24.335.4 68.7%   
Net profit margin %12.112.2 99.2%  
BALANCE SHEET DATA
Current assets Rs m68,74622,655 303.5%   
Current liabilities Rs m27,0276,681 404.5%   
Net working cap to sales %45.448.4 93.8%  
Current ratio x2.53.4 75.0%  
Inventory Days Days8565 131.2%  
Debtors Days Days9629 327.7%  
Net fixed assets Rs m24,132835 2,888.5%   
Share capital Rs m282213 132.8%   
"Free" reserves Rs m44,64316,715 267.1%   
Net worth Rs m44,92516,928 265.4%   
Long term debt Rs m45,3630-   
Total assets Rs m117,63924,162 486.9%  
Interest coverage x7.6163.7 4.7%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.81.4 57.2%   
Return on assets %11.416.8 68.3%  
Return on equity %24.723.7 104.1%  
Return on capital %19.136.9 51.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,152369 15,236.2%   
Fx outflow Rs m8,0843,807 212.4%   
Net fx Rs m48,068-3,438 -1,398.1%   
CASH FLOW
From Operations Rs m6,5741,527 430.5%  
From Investments Rs m-7,124-2,148 331.6%  
From Financial Activity Rs m5,432-1,024 -530.3%  
Net Cashflow Rs m1,992-1,646 -121.1%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 7.9 87.3%  
FIIs % 34.4 0.1 34,400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.1 61.4%  
Shareholders   56,727 18,270 310.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 14, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS